Yoichi Hamai
Overview
Explore the profile of Yoichi Hamai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Emi M, Hamai Y, Yoshikawa T, Hirohata R, Ohsawa M, Kurokawa T, et al.
Cancer Diagn Progn
. 2024 May;
4(3):276-280.
PMID: 38707736
Background/aim: This study aimed to evaluate the long-term prognosis of definitive chemoradiotherapy and clinical features of postoperative lymph node (LN) recurrence after curative resection of thoracic esophageal squamous cell cancer...
12.
Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, et al.
World J Surg
. 2024 Apr;
48(3):650-661.
PMID: 38686781
Background: There are few reports on the associations between lymph node (LN) status, determined by preoperative F-fluorodeoxyglucose-positron emission tomography (FDG-PET), and prognosis in patients with locally advanced esophageal squamous cell...
13.
Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Kurokawa T, et al.
World J Surg
. 2024 Feb;
48(2):416-426.
PMID: 38310312
Background: Pathological lymph node metastasis (LNM) following multimodal therapy is an important indicator of poor prognosis in patients with esophageal cancer. However, a significant number of patients without LNM are...
14.
Hirohata R, Hamai Y, Murakami Y, Emi M, Nishibuchi I, Kurokawa T, et al.
J Thorac Dis
. 2023 Nov;
15(10):5319-5329.
PMID: 37969281
Background: Esophageal fistula (EF) is a serious complication in patients with cT4b esophageal squamous cell carcinoma (ESCC) with adjacent organ involvement. Among EFs, aortoesophageal fistula (AEF), forming a fistula with...
15.
Hirano K, Hirohata R, Hamai Y, Yamaguchi S, Emi M, Yoshikawa T, et al.
Anticancer Res
. 2023 Jun;
43(7):3289-3293.
PMID: 37351985
Background/aim: Malignant esophageal neuroendocrine carcinoma (ENEC) is rare, and its prognosis is poor. Therefore, a standard strategy for treating ENEC remains controversial, and few reports have described a pathological complete...
16.
Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, et al.
Surg Today
. 2023 May;
54(1):53-63.
PMID: 37225930
Purpose: Various treatments are used for early postoperative recurrence of esophageal cancer, which has a poor prognosis. We evaluated the differences in outcomes and prognoses of each treatment modality between...
17.
Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, et al.
Front Oncol
. 2023 May;
13:1126536.
PMID: 37139161
Background: Nivolumab is approved in Japan as a second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) resistant to fluoropyrimidine and platinum-based drugs. It is also used in...
18.
Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Ohsawa M, et al.
Onco Targets Ther
. 2023 Apr;
16:263-273.
PMID: 37065776
Purpose: Various blood cell parameters have been identified as predictive markers of tumor responses and the survival of patients with cancer treated with immune checkpoint inhibitors. The purpose of this...
19.
Saito Y, Hamamoto Y, Hirata K, Yamasaki M, Watanabe M, Abe T, et al.
BMC Cancer
. 2023 Mar;
23(1):283.
PMID: 36978040
Background: Neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Chemoradiotherapy (CRT) is an alternative treatment approach. However, both treatments are...
20.
Miyoshi S, Nishibuchi I, Murakami Y, Katsuta T, Imano N, Hirokawa J, et al.
Int J Clin Oncol
. 2023 Jan;
28(3):382-391.
PMID: 36646953
Background: We evaluated the long-term results of definitive chemoradiotherapy (CRT) with elective nodal irradiation (ENI) using a three-dimensional (3D) planning system for resectable, locally advanced esophageal squamous cell carcinoma (LA-ESCC)....